ELI LILLY & Co Annual Report, Year Ended Dec 31, 2020

Eli Lilly and Company reported robust revenue growth of 10% in 2020, reaching $24.5 billion, driven primarily by strong volume increases in key products like Trulicity, Taltz, and Verzenio, as well as contributions from its COVID-19 therapies. Despite a decrease in gross margin percentage due to pricing pressures and increased rebates, the company saw a significant 34% increase in net income from continuing operations to $6.2 billion. Key to this performance were strategic acquisitions, including Dermira and Loxo Oncology, bolstering its late-stage pipeline in areas like immunology and oncology. The company also highlighted significant investments in R&D, particularly for COVID-19 treatments, and provided forward-looking guidance for 2021 expecting continued revenue growth and earnings per share. Lilly's strong market position and diverse product portfolio, coupled with ongoing pipeline development, position it for continued growth, although it remains subject to risks related to patent expirations, pricing pressures, and regulatory changes. The company's financial health appears solid, with a substantial increase in cash and cash equivalents and positive cash flow from operations. Lilly also continues to return value to shareholders through dividends and share repurchases. However, investors should remain aware of the potential impact of patent expiries on products like Alimta and the ongoing scrutiny of pharmaceutical pricing by governments and private payers worldwide. The company's forward-looking statements indicate an expectation of continued growth, but also acknowledge the dynamic nature of the pharmaceutical market and the ongoing need for innovation and strategic adaptation.